Levetiracetam Tablet, Film Coated
Product Images NDC 63187-360

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63187-360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (2c7560b9 9503 43bd 811d 13f6d3957081 01)

This is a formula for calculating the total daily dose in milliliters, based on the patient's weight and the daily dose in milligrams per kilogram. The concentration of the medication is 100 mg/mL.*

FDA Label Image

Figure 2 (2c7560b9 9503 43bd 811d 13f6d3957081 02)

This appears to be a formula for calculating the estimated glomerular filtration rate (eGFR) for female patients based on their age, weight, and serum creatinine levels. The equation takes into account adjustments for body surface area. The text seems to be a medical or scientific document.*

FDA Label Image

Structure (2c7560b9 9503 43bd 811d 13f6d3957081 03)

FDA Label Image

Figure 4 (2c7560b9 9503 43bd 811d 13f6d3957081 04)

FDA Label Image

Figure 5 (2c7560b9 9503 43bd 811d 13f6d3957081 05)

The text seems to show percentages of patients for different groups, possibly related to a medical study. However, given the lack of context and incomplete information, it is not possible to provide a more detailed description.*

FDA Label Image

Figure 6 (2c7560b9 9503 43bd 811d 13f6d3957081 06)

FDA Label Image

Figure 7 (2c7560b9 9503 43bd 811d 13f6d3957081 07)

This is a table showing the percentage of patients in a study that took placebo and levetiracetam. The percentages range from 0% to 44.6%, with the majority of patients taking levetiracetam. There is no further information available.*

FDA Label Image

Figure 8 (2c7560b9 9503 43bd 811d 13f6d3957081 08)

This appears to be a statistical data report representing the percentage of patients who received Placebo (51 patients) and Levetiracetam (58 patients). The percentage of patients who received Placebo is 19.6% while the percentage of patients who received Levetiracetam is 43.1%.*

FDA Label Image

Figure 9 (2c7560b9 9503 43bd 811d 13f6d3957081 09)

This is a chart representing the percentage of patients in two groups (placebo and levetiracetam) based on an unknown criterion. The x-axis has 10 points ranging from 0 to 100%, while the y-axis is not labeled. The placebo group has 84 patients, and the levetiracetam group has 79 patients.*

FDA Label Image

63187-360-60 (2c7560b9 9503 43bd 811d 13f6d3957081 12)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.